Arizona Heart Institute Study Demonstrates CardioDynamics' BioZ Parameters Associated with Improvement in Quality of Life.

Business Editors & Health/Medical Writers

BIOWIRE2K

SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2002

Quality of Life Proven to be a Powerful Predictor of

Hospitalization and Mortality

CardioDynamics (Nasdaq:CDIC), the innovator and leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ(R) noninvasive digital cardiac function monitoring systems, today announced the results of an important ICG clinical study by the Arizona Heart Institute (AHI) at the American College of Chest Physicians (ACCP) meeting in San Diego.

The study's results indicated that the hemodynamic data derived from the BioZ is directly associated with quality of life and the New York Heart Association (NYHA) functional class in chronic, decompensated heart failure patients.

Researchers at AHI initially obtained baseline measurements of ICG, NYHA class assessment, a six-minute walk, quality of life questionnaire (Minnesota Living with Heart Failure Questionnaire), echocardiogram, and B-Type Natriuretic Peptide (BNP) testing. The same measurements were taken three months later and the results showed that as the ICG measurements of left ventricular ejection time (LVET), pre-ejection period (PEP) and systolic time ratio (STR) improved, so did the measurements of quality of life and NYHA class assessment. Studies have shown results of a quality of life assessment to be a powerful predictor of hospitalization and mortality. Additionally, in order to determine the best course of therapy, physicians often assess the stage of heart failure according to the NYHA functional classification system.

"We found ICG to be an excellent, cost-effective method for measuring the electromechanical performance of the heart," stated Kris Vijay, M.D., Director of Heart Failure and Clinical Research, Arizona Heart Institute, Phoenix. "In this Study, improvement in LVET, PEP and STR measurements were directly associated with improvement in functional class and quality of life. There is significant power in the quality of life association, as quality of life is well-documented to be a predictor of hospitalization and mortality. In another study presented at the Heart Failure Society meeting, BNP did not correlate with improvement in functional class at three months. The BioZ minimizes the subjectivity of quality of life and NYHA functional class and provides a more objective assessment. With the BioZ, objective patient management with good clinical outcomes can be accomplished at no significant risk as compared to invasive pulmonary artery catheter monitoring."

Heart failure is a major public health problem in this country and is responsible for more than 11 million physician visits, and considerable mortality and morbidity rates. According to the American Heart Association, the annual costs for congestive heart failure is estimated to be $23 billion.

Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We have committed to Medicare and the leaders in heart failure to be part of a cost-effective solution in addressing the staggering costs associated with cardiovascular disease. Each new study is demonstrating BioZ's role in cost-effectively and efficiently monitoring and treating these patients. Studies by respected institutions, such as the Arizona Heart Institute, will help further drive our proprietary technology as a new standard of care in noninvasive cardiac medicine."

About CardioDynamics:

CardioDynamics (Nasdaq:CDIC), the ICG Company, is the innovator and global leader of breakthrough medical technology called Impedance Cardiography (ICG). The company's primary products, the BioZ(R) Systems, are being used by leading physicians around the world to help battle the number one killer of men and women -- cardiovascular disease. Partners include GE Medical Systems Information Technologies, Philips Medical Systems, Spacelabs Medical Systems and Vasomedical. The worldwide market potential for BioZ products is estimated to be $5 billion and an additional $800 million in recurring annual revenue for disposables. For additional information or to request an investor package, please refer to the company's Web site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Note: Except for the historical and factual information contained herein, this press release contains forward-looking statements relating to initiation of protocols, impact of clinical studies, strategic partners, market size and adoption rates, the accuracy of which are necessarily subject to uncertainties and risks, which include sole dependence on the BioZ product line, and various uncertainties characteristic of early stage medical technology companies; as well as other risks detailed in the company's filings with the SEC, including its 2001 Form 10-K. The company does not undertake to update the disclosures contained in this press release.